A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey

被引:54
|
作者
Ozgoztasi, O [1 ]
Baydar, I [1 ]
机构
[1] GAZIANTEP UNIV,DEPT DERMATOL & INFECT DIS,GAZIANTEP,TURKEY
关键词
D O I
10.1046/j.1365-4362.1997.00022.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
An open-labeled, randomized clinical trial to evaluate the efficacy of paromomycin ointment as compared with ketoconazole was conducted on seventy-two patients of both sexes and different ages with the confirmed diagnosis of cutaneous leishmaniasis (CL). All patients had a complete clinical evaluation for other diseases. Patients were excluded if they were pregnant or nursing or if they had serious concomitant diseases. Patients were divided randomly into two treatment groups: in the first group 40 patients were treated with an ointment containing 15% paromomycin sulfate and 12% methylbenzothonium chloride in white soft paraffin (labeled as p-ointment by El-On(1)) twice daily for 15 days. Treated lesions were left uncovered. The second group consisted of 32 patients who received ketoconazole 400 mg/day orally for 30 days. This dosage was reduced to 200 mg/day for patients below 12 years of age. In all cases the diagnosis was based on positive smear and/or culture. Direct smears were prepared from the exudate obtained by a small incision made at the edge of the lesion with a sterile surgical blade or lancet and stained using the Giemsa method for leishmania bodies (Pig. 1). In smear negative and suspected cases aspirates taken by puncturing the lesions were inoculated onto NNN (Novy, McNeal, Nicolle) medium for culture. The cultures were incubated at 28 degrees C and the development of motile promastigotes was observed. Clinical and parasitological evaluations of the patients were performed at the end of the treatment period and 4 weeks post-treatment. A cure was defined as complete healing and disappearance of the lesion or reversible hypopigmentation at the site of lesion. Incomplete or partial improvement was defined as a reduction in the size of a lesion and the absence of parasites on smear or culture. A treatment failure was defined as the absence of any changes in the lesion and persistence of parasites on smear or culture.
引用
下载
收藏
页码:61 / 63
页数:3
相关论文
共 50 条
  • [1] A RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN TUNISIA TREATING CUTANEOUS LEISHMANIASIS WITH PAROMOMYCIN OINTMENT
    BENSALAH, A
    ZAKRAOUI, H
    ZAATOUR, A
    FTAITI, A
    ZAAFOURI, B
    GARRAOUI, A
    OLLIARO, PL
    DELLAGI, K
    BENISMAIL, R
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1995, 53 (02): : 162 - 166
  • [2] TOPICAL TREATMENT WITH PAROMOMYCIN FOR CUTANEOUS LEISHMANIASIS
    BENAMITAI, D
    DANON, Y
    ASHKENAZI, S
    GARTY, BZ
    JOURNAL OF DERMATOLOGICAL TREATMENT, 1995, 6 (02) : 65 - 67
  • [3] Topical Paromomycin for treating solitary mucosal leishmaniasis
    Kassem, Riad
    Peretz, Avi
    Ben Amy, Dalit Porat
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2018, 57 (06) : 721 - 723
  • [4] Topical Paromomycin with or without Gentamicin for Cutaneous Leishmaniasis
    Ben Salah, Afif
    Ben Messaoud, Nathalie
    Guedri, Evelyn
    Zaatour, Amor
    Ben Alaya, Nissaf
    Bettaieb, Jihene
    Gharbi, Adel
    Hamida, Nabil Belhadj
    Boukthir, Aicha
    Chlif, Sadok
    Abdelhamid, Kidar
    El Ahmadi, Zaher
    Louzir, Hechmi
    Mokni, Mourad
    Morizot, Gloria
    Buffet, Pierre
    Smith, Philip L.
    Kopydlowski, Karen M.
    Kreishman-Deitrick, Mara
    Smith, Kirsten S.
    Nielsen, Carl J.
    Ullman, Diane R.
    Norwood, Jeanne A.
    Thorne, George D.
    McCarthy, William F.
    Adams, Ryan C.
    Rice, Robert M.
    Tang, Douglas
    Berman, Jonathan
    Ransom, Janet
    Magill, Alan J.
    Grogl, Max
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (06): : 524 - 532
  • [5] Topical treatment of persistent cutaneous leishmaniasis with paromomycin
    Flaig, M. J.
    Rupec, J.
    Ruzicka, T.
    Rupec, R. A.
    HAUTARZT, 2007, 58 (08): : 689 - +
  • [6] THE EFFICACY OF TOPICAL KETOCONAZOLE IN CUTANEOUS LEISHMANIASIS
    ABAHUSAIN, A
    ALKHAWAJAH, A
    ALGINDAN, Y
    JAIN, S
    LARBI, E
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (05) : P645 - P645
  • [7] Topical paromomycin for New World cutaneous leishmaniasis
    Sosa, Nestor
    Miguel Pascale, Juan
    Jimenez, Ana I.
    Norwood, Jeanne A.
    Kreishman-Detrick, Mara
    Weina, Peter J.
    Lawrence, Kendra
    McCarthy, William F.
    Adams, Ryan C.
    Scott, Charles
    Ransom, Janet
    Tang, Douglas
    Grogl, Max
    PLOS NEGLECTED TROPICAL DISEASES, 2019, 13 (05):
  • [8] PLACEBO-CONTROLLED CLINICAL-TRIAL OF SODIUM STIBOGLUCONATE (PENTOSTAM) VERSUS KETOCONAZOLE FOR TREATING CUTANEOUS LEISHMANIASIS IN GUATEMALA
    NAVIN, TR
    ARANA, BA
    ARANA, FE
    BERMAN, JD
    CHAJON, JF
    JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (03): : 528 - 534
  • [9] EVALUATION OF TOPICAL KETOCONAZOLE IN CUTANEOUS-LEISHMANIASIS
    ABAHUSEIN, A
    LARBI, EB
    ALKHAWAJAH, A
    ALGINDAN, Y
    JAIN, S
    EAST AFRICAN MEDICAL JOURNAL, 1992, 69 (01) : 14 - 17
  • [10] Topical terbinafine in the treatment of cutaneous leishmaniasis: triple blind randomized clinical trial
    Farajzadeh S.
    Heshmatkhah A.
    Vares B.
    Mohebbi E.
    Mohebbi A.
    Aflatoonian M.
    Eybpoosh S.
    Sharifi I.
    Aflatoonian M.R.
    Shamsi Meymandi S.
    Fekri A.R.
    Mostafavi M.
    Journal of Parasitic Diseases, 2016, 40 (4) : 1159 - 1164